Kyverna Therapeutics Past Earnings Performance
Past criteria checks 0/6
Kyverna Therapeutics's earnings have been declining at an average annual rate of -115.3%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been declining at an average rate of 100% per year.
Key information
-115.3%
Earnings growth rate
82.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -100.0% |
| Return on equity | -21.0% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Kyverna Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -76 | 16 | 0 |
| 31 Dec 23 | 0 | -60 | 12 | 0 |
| 30 Sep 23 | 0 | -48 | 10 | 0 |
| 31 Dec 22 | 7 | -29 | 8 | 0 |
| 31 Dec 21 | 6 | -26 | 6 | 0 |
Quality Earnings: KYTX is currently unprofitable.
Growing Profit Margin: KYTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KYTX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KYTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KYTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: KYTX has a negative Return on Equity (-21.03%), as it is currently unprofitable.